Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2013, Article ID 946392, 4 pages
Case Report

A Patient with HIV Treated with Ipilimumab and Stereotactic Radiosurgery for Melanoma Metastases to the Brain

1Departments of Neurosurgery, The Johns Hopkins University School of Medicine, Phipps 123 600 N. Wolfe Street, Baltimore, MD 21287, USA
2University of Maryland School of Medicine, Baltimore, MD 21210, USA
3Department of Radiation Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
4Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA

Received 17 September 2013; Accepted 31 October 2013

Academic Editors: K. Jamil and P. F. Lenehan

Copyright © 2013 Jacob Ruzevick et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Cancers, such as melanoma, that are associated with immune deficiencies are a major cause of morbidity and mortality in HIV-infected patients. Once patients develop melanoma metastases to the brain, treatment is often limited to palliative surgery and/or radiation. Ipilimumab, a CTLA-4 antagonist, has been shown to improve the median survival of patients with metastatic melanoma. However, available data regarding the safety and efficacy of ipilimumab in HIV-infected patients who develop intracranial melanoma metastases is limited. Here we report our experience administering ipilimumab to a patient with HIV-AIDS who developed multiple intracranial melanoma metastases. Following treatment, our patient showed improvement in systemic tumor control without any apparent interference with antiretroviral treatment.